BGNE240920C195000
- 5.65
- +0.75+15.31%
BeiGene Newsroom
BeiGene Says Israeli Ministry Of Health Approved TEVIMBRA (Tislelizumab) As Monotherapy For Treatment Of Adult Patients With Unresectable Or Metastatic OESCC After Prior Systemic Chemotherapy
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
Hong Kong stocks turned around in the afternoon! Both Hang Seng Index and Technology Index reversed and rose, what happened?
Analysts believe that, under the current circumstances, both the Hong Kong stock market and the A-share market need policies as triggers. If China's stimulus policies can timely follow and exceed expectations after the Fed rate cut, the market may usher in a wave of prosperity.
US stock preview | Earnings guidance exceeds expectations! Oracle continues to rise more than 6% pre-market; Is the US stock correction over? Deutsche Bank: Three major bullish factors may support new highs in US stocks.
The Q4 revenue outlook does not highlight the profitability improvement of AI, and Adobe's pre-market plunge exceeds 8%; Fitch: The Fed's rate cut should be gradual rather than hasty, and is expected to make a moderate 250 basis point rate cut over the next two years; Will the Fed's rate cut signal be sounded? Goldman Sachs executives highly recommend small-cap stock hunting.
Beigene's stock rose nearly 2% pre-market as the National Medical Products Administration accelerated the approval of clinical pharmaceuticals.
On September 13th, Beigene (BGNE.US) rose 1.9% pre-market to $200. The State Council Information Office held a series of themed press conferences on "Promoting High-Quality Development" today. Li Li, the director of the National Medical Products Administration, introduced that the NMPA is accelerating the evaluation and approval of urgently needed clinical products, and will include eligible products in the priority evaluation and approval process. The time limit for the evaluation and approval of innovative drug clinical trials will be shortened from 60 working days to 30 working days.
Hong Kong pharmaceutical stocks continue to rise! The National Medical Products Administration accelerates the approval of clinical drugs, institutions are bullish on the rapid development of innovative drugs.
Soochow Securities has released a research report stating that the development of domestic new drugs in various stages of clinical trials and the participation of domestic new drugs in international multicenter clinical trials reflect a significant enhancement of China's research and development capabilities.
BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk
New Additions to Roth MKM's ADR Portfolio for September
US stocks outlook: August PPI slightly lower than expected, three major futures indexes slightly lower; downgraded by major banks! Micron Technology pre-market fell more than 3%
Goldman Sachs CEO: There are signs of weakness in the job market, and the Fed may still cut interest rates by 50 basis points. UBS Group CEO: The market's expectation for a rate cut by the Fed is too aggressive, bullish on a soft landing for the US economy. Nvidia soared 8% overnight and saved the US stock market! Multiple call options made 10 times the profit.
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Beigene responds to AbbVie's lawsuit accusing it of stealing trade secrets: intending to obstruct the development process.
Beigene stated that the development of the BGB-16673 project will not be interrupted by this lawsuit.
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Beigene's stock price was hit by bearish news! It is accused of stealing trade secrets. The company denies the accusations and vows to vigorously defend itself.
①AbbVie has once again filed a lawsuit against Beigene, accusing Beigene of stealing core business secrets to develop BTK degraders. ②Previously, AbbVie sued Beigene for patent infringement of zanubrutinib (BTK inhibitor), and the case is under review. Beigene stated that this has not had a negative impact on the research and sales of zanubrutinib in the United States.
Beigene (06160.HK) denies the allegation of stealing AbbVie (ABBV.US)'s BTK degrader commercial secret.
According to the report from Interface News, beigene (06160.HK) denies the accusations made by AbbVie (ABBV.US) of stealing its BTK degrader commercial secrets. beigene will firmly defend its own intellectual property rights and mount a strong defense against the accusations launched by AbbVie. Currently, beigene is carefully reviewing AbbVie's allegations and will provide a suitable response through legal procedures.
Express News | Beigene responded to AbbVie's lawsuit: denied the allegations and will launch a strong defense.
US stocks gold rush | or become the biggest winner of the election debate! First Solar surged 15%; Is the wave of production cuts coming? The stock prices of two major lithium mining companies soared by more than 10% in response.
IBM's cloud computing business is strong, with its stock price hitting a new historical high, and has risen over 20% this year; business growth is benefiting from AI engines, with AppLovin's daily increase of 13.15%.
Express News | Stock market review of the STAR Market: Few hot spots on the market, Beigene leads the decline in pharmaceutical stocks.
Express News | The innovative drugs sector has experienced a volatile decline, with Beigene falling more than 10%.
Express News | Some China concept stocks rose against the market, beigene surged over 7%, xpeng surged nearly 5%, bilibili surged nearly 4%.
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading